We are leveraging our proprietary Targeted Alpha Therapies platform and Fast-ClearTM linker technology to advance a pipeline of alpha-based therapeutic programs to treat various cancers.
[225Ac]-FPI-1434 is our lead clinical candidate engineered to deliver alpha particles to cancer cells. The new drug was created by combining an antibody for an established cancer biomarker, IGF-1R, with our Fast-Clear™ linker technology to create a Targeted Alpha Therapy that has the potential to be used across multiple tumor types. IGF-1R is a well-established tumor target found on numerous types of cancer cells. We rely on IGF-1R simply as a way to identify and target the tumor to deliver our alpha emitting payload.